Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.05
ZBH's Cash-to-Debt is ranked lower than
97% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. ZBH: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
ZBH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.67 Max: 4.45
Current: 0.05
0.05
4.45
Equity-to-Asset 0.45
ZBH's Equity-to-Asset is ranked lower than
74% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ZBH: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
ZBH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11  Med: 0.65 Max: 0.82
Current: 0.45
0.11
0.82
Debt-to-Equity 0.86
ZBH's Debt-to-Equity is ranked lower than
87% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 0.28 vs. ZBH: 0.86 )
Ranked among companies with meaningful Debt-to-Equity only.
ZBH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02  Med: 0.27 Max: 4.62
Current: 0.86
0.02
4.62
Debt-to-EBITDA 5.42
ZBH's Debt-to-EBITDA is ranked lower than
82% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. ZBH: 5.42 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ZBH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.34  Med: 1.2 Max: 9.98
Current: 5.42
0.34
9.98
Interest Coverage 2.51
ZBH's Interest Coverage is ranked lower than
93% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 68.39 vs. ZBH: 2.51 )
Ranked among companies with meaningful Interest Coverage only.
ZBH' s Interest Coverage Range Over the Past 10 Years
Min: 1.63  Med: 15.23 Max: 49.46
Current: 2.51
1.63
49.46
Piotroski F-Score: 6
Altman Z-Score: 1.46
Beneish M-Score: -2.50
WACC vs ROIC
8.94%
5.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 10.52
ZBH's Operating Margin % is ranked higher than
72% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. ZBH: 10.52 )
Ranked among companies with meaningful Operating Margin % only.
ZBH' s Operating Margin % Range Over the Past 10 Years
Min: 7.79  Med: 22.6 Max: 26.45
Current: 10.52
7.79
26.45
Net Margin % 23.51
ZBH's Net Margin % is ranked higher than
93% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 1.42 vs. ZBH: 23.51 )
Ranked among companies with meaningful Net Margin % only.
ZBH' s Net Margin % Range Over the Past 10 Years
Min: 2.45  Med: 16.88 Max: 23.51
Current: 23.51
2.45
23.51
ROE % 17.66
ZBH's ROE % is ranked higher than
88% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. ZBH: 17.66 )
Ranked among companies with meaningful ROE % only.
ZBH' s ROE % Range Over the Past 10 Years
Min: 1.79  Med: 12.78 Max: 17.66
Current: 17.66
1.79
17.66
ROA % 6.92
ZBH's ROA % is ranked higher than
77% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: -0.20 vs. ZBH: 6.92 )
Ranked among companies with meaningful ROA % only.
ZBH' s ROA % Range Over the Past 10 Years
Min: 0.8  Med: 7.98 Max: 12.23
Current: 6.92
0.8
12.23
ROC (Joel Greenblatt) % 18.71
ZBH's ROC (Joel Greenblatt) % is ranked higher than
68% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 3.76 vs. ZBH: 18.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ZBH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 11.65  Med: 38.54 Max: 50.68
Current: 18.71
11.65
50.68
3-Year Revenue Growth Rate 12.20
ZBH's 3-Year Revenue Growth Rate is ranked higher than
72% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. ZBH: 12.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ZBH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.9  Med: 10.9 Max: 25.6
Current: 12.2
4.9
25.6
3-Year EBITDA Growth Rate 4.60
ZBH's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 235 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ZBH: 4.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ZBH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -9.2  Med: 7.3 Max: 39.7
Current: 4.6
-9.2
39.7
3-Year EPS without NRI Growth Rate 29.10
ZBH's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 228 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ZBH: 29.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ZBH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.6  Med: 8.9 Max: 41.7
Current: 29.1
-43.6
41.7
GuruFocus has detected 3 Warning Signs with Zimmer Biomet Holdings Inc ZBH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ZBH's 30-Y Financials

Financials (Next Earnings Date: 2018-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

ZBH Guru Trades in Q1 2017

Larry Robbins 771,410 sh (New)
John Buckingham 41,124 sh (New)
Caxton Associates 3,300 sh (New)
Paul Tudor Jones 260,450 sh (+8581.67%)
Joel Greenblatt 164,266 sh (+386.96%)
Steven Cohen 1,053,500 sh (+230.25%)
Richard Snow 535,924 sh (+75.33%)
Pioneer Investments 120,968 sh (+60.31%)
Mario Gabelli 275,242 sh (+22.89%)
Mairs and Power 1,059,960 sh (+8.27%)
Scott Black 22,647 sh (+1.14%)
Jeff Auxier 86,614 sh (+0.12%)
Eaton Vance Worldwide Health Sciences Fund 282,439 sh (unchged)
Ray Dalio Sold Out
Private Capital 96,339 sh (-0.18%)
PRIMECAP Management 443,800 sh (-1.38%)
HOTCHKIS & WILEY 1,555,689 sh (-2.26%)
Jeremy Grantham 664,573 sh (-2.58%)
John Rogers 1,076,908 sh (-4.66%)
Ken Fisher 132,791 sh (-9.82%)
Robert Olstein 136,645 sh (-20.47%)
First Eagle Investment 494 sh (-43.41%)
» More
Q2 2017

ZBH Guru Trades in Q2 2017

Richard Pzena 2,023 sh (New)
Jana Partners 3,195,300 sh (New)
Andreas Halvorsen 397,654 sh (New)
David Dreman 8,236 sh (New)
Scott Black 42,878 sh (+89.33%)
PRIMECAP Management 665,600 sh (+49.98%)
Mario Gabelli 312,843 sh (+13.66%)
John Buckingham 44,429 sh (+8.04%)
Jeremy Grantham 680,934 sh (+2.46%)
Mairs and Power 1,078,427 sh (+1.74%)
First Eagle Investment 494 sh (unchged)
Jana Partners 804,700 sh (unchged)
Steven Cohen 75,000 sh (unchged)
Larry Robbins 771,410 sh (unchged)
Jeff Auxier 86,614 sh (unchged)
Caxton Associates Sold Out
Ken Fisher 132,184 sh (-0.46%)
John Rogers 1,062,051 sh (-1.38%)
Private Capital 94,939 sh (-1.45%)
Richard Snow 524,554 sh (-2.12%)
HOTCHKIS & WILEY 1,419,564 sh (-8.75%)
Pioneer Investments 108,068 sh (-10.66%)
Robert Olstein 110,760 sh (-18.94%)
Steven Cohen 618,700 sh (-41.27%)
Joel Greenblatt 87,579 sh (-46.68%)
Paul Tudor Jones 14,929 sh (-94.27%)
Eaton Vance Worldwide Health Sciences Fund 202,239 sh (-28.40%)
» More
Q3 2017

ZBH Guru Trades in Q3 2017

George Soros 62,500 sh (New)
Barrow, Hanley, Mewhinney & Strauss 355 sh (New)
Larry Robbins 3,155,386 sh (+309.04%)
David Dreman 16,472 sh (+100.00%)
Joel Greenblatt 156,568 sh (+78.77%)
Mario Gabelli 485,919 sh (+55.32%)
Jana Partners 4,662,497 sh (+45.92%)
Robert Olstein 132,700 sh (+19.81%)
Steven Cohen 697,900 sh (+12.80%)
John Buckingham 46,108 sh (+3.78%)
Mairs and Power 1,096,486 sh (+1.67%)
Richard Pzena 2,023 sh (unchged)
First Eagle Investment 494 sh (unchged)
Pioneer Investments Sold Out
Andreas Halvorsen Sold Out
Jeff Auxier 86,544 sh (-0.08%)
John Rogers 1,057,463 sh (-0.43%)
PRIMECAP Management 661,100 sh (-0.68%)
Richard Snow 517,234 sh (-1.40%)
Ken Fisher 130,255 sh (-1.46%)
Jeremy Grantham 641,484 sh (-5.79%)
HOTCHKIS & WILEY 1,336,964 sh (-5.82%)
Private Capital 88,219 sh (-7.08%)
Scott Black 21,573 sh (-49.69%)
Paul Tudor Jones 4,150 sh (-72.20%)
Eaton Vance Worldwide Health Sciences Fund 182,716 sh (-9.65%)
» More
Q4 2017

ZBH Guru Trades in Q4 2017

Pioneer Investments 98,979 sh (New)
Paul Tudor Jones 23,029 sh (+454.92%)
George Soros 130,500 sh (+108.80%)
Joel Greenblatt 306,781 sh (+95.94%)
PRIMECAP Management 868,100 sh (+31.31%)
Richard Pzena 2,641 sh (+30.55%)
Robert Olstein 142,210 sh (+7.17%)
Mario Gabelli 516,794 sh (+6.35%)
Barrow, Hanley, Mewhinney & Strauss 377 sh (+6.20%)
Jeff Auxier 87,269 sh (+0.84%)
Mairs and Power 1,102,964 sh (+0.59%)
John Buckingham 46,305 sh (+0.43%)
Richard Snow 517,877 sh (+0.12%)
First Eagle Investment 494 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Jeremy Grantham Sold Out
Larry Robbins Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
HOTCHKIS & WILEY 1,336,764 sh (-0.01%)
Scott Black 21,405 sh (-0.78%)
Private Capital 87,194 sh (-1.16%)
John Rogers 1,005,470 sh (-4.92%)
Ken Fisher 122,743 sh (-5.77%)
Jana Partners 3,854,500 sh (-17.33%)
Steven Cohen 512,686 sh (-26.54%)
David Dreman 363 sh (-97.80%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:ZBH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
HOTCHKIS & WILEY 2017-12-31 Reduce -0.01%$108.72 - $124.46 $ 118.852%1,336,764
John Rogers 2017-12-31 Reduce -4.92%0.07%$108.72 - $124.46 $ 118.852%1,005,470
Mario Gabelli 2017-12-31 Add 6.35%0.02%$108.72 - $124.46 $ 118.852%516,794
Joel Greenblatt 2017-12-31 Add 95.94%0.26%$108.72 - $124.46 $ 118.852%306,781
Robert Olstein 2017-12-31 Add 7.17%0.15%$108.72 - $124.46 $ 118.852%142,210
George Soros 2017-12-31 Add 108.80%0.23%$108.72 - $124.46 $ 118.852%130,500
Ken Fisher 2017-12-31 Reduce -5.77%$108.72 - $124.46 $ 118.852%122,743
Private Capital 2017-12-31 Reduce -1.16%0.02%$108.72 - $124.46 $ 118.852%87,194
Richard Pzena 2017-12-31 Add 30.55%$108.72 - $124.46 $ 118.852%2,641
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Add 6.20%$108.72 - $124.46 $ 118.852%377
David Dreman 2017-12-31 Reduce -97.80%1.09%$108.72 - $124.46 $ 118.852%363
HOTCHKIS & WILEY 2017-09-30 Reduce -5.82%0.04%$110.13 - $132.61 $ 118.85-0%1,336,964
John Rogers 2017-09-30 Reduce -0.43%0.01%$110.13 - $132.61 $ 118.85-0%1,057,463
Mario Gabelli 2017-09-30 Add 55.32%0.12%$110.13 - $132.61 $ 118.85-0%485,919
Joel Greenblatt 2017-09-30 Add 78.77%0.12%$110.13 - $132.61 $ 118.85-0%156,568
Robert Olstein 2017-09-30 Add 19.81%0.33%$110.13 - $132.61 $ 118.85-0%132,700
Ken Fisher 2017-09-30 Reduce -1.46%$110.13 - $132.61 $ 118.85-0%130,255
Private Capital 2017-09-30 Reduce -7.08%0.14%$110.13 - $132.61 $ 118.85-0%88,219
George Soros 2017-09-30 New Buy0.22%$110.13 - $132.61 $ 118.85-0%62,500
David Dreman 2017-09-30 Add 100.00%0.56%$110.13 - $132.61 $ 118.85-0%16,472
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 New Buy$110.13 - $132.61 $ 118.85-0%355
HOTCHKIS & WILEY 2017-06-30 Reduce -8.75%0.06%$116.54 - $129.39 $ 118.85-3%1,419,564
John Rogers 2017-06-30 Reduce -1.38%0.02%$116.54 - $129.39 $ 118.85-3%1,062,051
Mario Gabelli 2017-06-30 Add 13.66%0.03%$116.54 - $129.39 $ 118.85-3%312,843
Ken Fisher 2017-06-30 Reduce -0.46%$116.54 - $129.39 $ 118.85-3%132,184
Robert Olstein 2017-06-30 Reduce -18.94%0.41%$116.54 - $129.39 $ 118.85-3%110,760
Private Capital 2017-06-30 Reduce -1.45%0.03%$116.54 - $129.39 $ 118.85-3%94,939
Joel Greenblatt 2017-06-30 Reduce -46.68%0.12%$116.54 - $129.39 $ 118.85-3%87,579
David Dreman 2017-06-30 New Buy0.58%$116.54 - $129.39 $ 118.85-3%8,236
Richard Pzena 2017-06-30 New Buy$116.54 - $129.39 $ 118.85-3%2,023
HOTCHKIS & WILEY 2017-03-31 Reduce -2.26%0.01%$103.33 - $122.11 $ 118.852%1,555,689
John Rogers 2017-03-31 Reduce -4.66%0.06%$103.33 - $122.11 $ 118.852%1,076,908
Mario Gabelli 2017-03-31 Add 22.89%0.04%$103.33 - $122.11 $ 118.852%275,242
Joel Greenblatt 2017-03-31 Add 386.96%0.2%$103.33 - $122.11 $ 118.852%164,266
Robert Olstein 2017-03-31 Reduce -20.47%0.47%$103.33 - $122.11 $ 118.852%136,645
Ken Fisher 2017-03-31 Reduce -9.82%$103.33 - $122.11 $ 118.852%132,791
Private Capital 2017-03-31 Reduce -0.18%$103.33 - $122.11 $ 118.852%96,339
First Eagle Investment 2017-03-31 Reduce -43.41%$103.33 - $122.11 $ 118.852%494
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NYSE:EW, NAS:ALGN, LSE:SN., NYSE:TFX, NYSE:BSX, NYSE:VAR, NAS:ABMD, XSWX:SOON, OCSE:WDH, ASX:COH, SZSE:300003, XPAR:DIM, LSE:CTEC, NZSE:FPH, NAS:MASI, NYSE:GMED, OCSE:AMBU B, OCSE:GN, NAS:LIVN, NAS:IART » details
Traded in other countries:ZIM.Germany, ZBH.Switzerland, 0QQD.UK,
Headquarter Location:USA
Zimmer Biomet Holdings Inc is a medical device company. It designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery under brands like NexGen, VerSys, SoPlus, and Pulsavac.

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. It distributes and sells its products to hospitals and clinics worldwide under brand names like NexGen, Zimmer, VerSys, SoPlus, and Pulsavac.

Guru Investment Theses on Zimmer Biomet Holdings Inc

Jeff Auxier Comments on Zimmer Biomet Holdings - May 09, 2017

Zimmer Biomet (NYSE:ZBH) has a leading musculoskeletal portfolio and is the global market share leader in knees and hips. Zimmer is also predicting $2B in annual free cash flow by 2020. At year end the stock traded down to a steep discount to the market, an attractive 12 times earnings. The demographics favor hips and knees as the peak year is age 68—about the average age for baby boomers. According to the Pew Research Center, roughly 10,000 Americans turn 65 every day. Pain is a good motivator for action.

From Jeff Auxier (Trades, Portfolio)'s Auxier Asset Management first quarter 2017 shareholder letter.

Check out Jeff Auxier latest stock trades

John Rogers Comments on Zimmer Biomet Holdings - Jan 20, 2017

Other holdings underperformed. Orthopedic specialist Zimmer Biomet Holdings, Inc. (NYSE:ZBH) fell –20.44% after cutting guidance and admitting internal supply issues. Earnings were in-line, but revenue was negatively impacted by inventory for some high-end products. The company subsequently cut full-year earnings guidance from $8.00 per share to $ 7.95 per share. We view the supply problem as a short-term issue and believe the long-term future is bright for this best-in-class brand.

From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund fourth quarter 2016 commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Zimmer Biomet Holdings Inc

David Dreman Sells Goldman Sachs, AT&T, CVS The guru's largest sales of the 4th quarter
The founder and chairman of Dreman Value Management LLC, David Dreman (Trades, Portfolio), sold shares in the following stocks during the fourth quarter. Read more...
Zimmer Biomet's Rapid Recovery Program Marks Two Decades of Success in Europe
Zimmer Biomet Holdings Announces Audio Webcast and Conference Call of Fourth Quarter and Full-Year 2017 Results
Zimmer Biomet Announces FDA Clearance of the Sidus® Stem-Free Shoulder System
Zimmer Biomet to Present at 36th Annual J.P. Morgan Healthcare Conference
Zimmer Biomet Announces Publication of Positive Results from PROGRESS II Trial of Autologous Protein Solution Prepared with nSTRIDE® APS Kit in Treating Osteoarthritis of the Knee
Zimmer Biomet Announces Appointment of Bryan C. Hanson as President and Chief Executive Officer
Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2017
Zimmer Biomet to Present at 29th Annual Piper Jaffray Healthcare Conference
Report: Exploring Fundamental Drivers Behind CalAtlantic, EOG, Treehouse, Zimmer Biomet, NiSource, and Viavi – New Horizons, Emerging Trends, and Upcoming Developments

Ratios

vs
industry
vs
history
PE Ratio 13.19
ZBH's PE Ratio is ranked higher than
86% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 28.67 vs. ZBH: 13.19 )
Ranked among companies with meaningful PE Ratio only.
ZBH' s PE Ratio Range Over the Past 10 Years
Min: 9.07  Med: 20.65 Max: 397
Current: 13.19
9.07
397
Forward PE Ratio 14.99
ZBH's Forward PE Ratio is ranked higher than
92% of the 48 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. ZBH: 14.99 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 13.19
ZBH's PE Ratio without NRI is ranked higher than
87% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 28.67 vs. ZBH: 13.19 )
Ranked among companies with meaningful PE Ratio without NRI only.
ZBH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.07  Med: 20.65 Max: 397
Current: 13.19
9.07
397
Price-to-Owner-Earnings 30.19
ZBH's Price-to-Owner-Earnings is ranked higher than
58% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 35.70 vs. ZBH: 30.19 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ZBH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.03  Med: 20.46 Max: 110.83
Current: 30.19
9.03
110.83
PB Ratio 2.05
ZBH's PB Ratio is ranked higher than
67% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.85 vs. ZBH: 2.05 )
Ranked among companies with meaningful PB Ratio only.
ZBH' s PB Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.19 Max: 4.21
Current: 2.05
1.31
4.21
PS Ratio 3.09
ZBH's PS Ratio is ranked higher than
53% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.19 vs. ZBH: 3.09 )
Ranked among companies with meaningful PS Ratio only.
ZBH' s PS Ratio Range Over the Past 10 Years
Min: 1.82  Med: 3.11 Max: 6.16
Current: 3.09
1.82
6.16
Price-to-Free-Cash-Flow 22.24
ZBH's Price-to-Free-Cash-Flow is ranked higher than
67% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 31.00 vs. ZBH: 22.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ZBH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.53  Med: 21.86 Max: 50.44
Current: 22.24
9.53
50.44
Price-to-Operating-Cash-Flow 15.31
ZBH's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 20.56 vs. ZBH: 15.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ZBH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.88  Med: 13.89 Max: 25.25
Current: 15.31
6.88
25.25
EV-to-EBIT 41.73
ZBH's EV-to-EBIT is ranked lower than
79% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 24.04 vs. ZBH: 41.73 )
Ranked among companies with meaningful EV-to-EBIT only.
ZBH' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 14.7 Max: 80.8
Current: 41.73
6.8
80.8
EV-to-EBITDA 18.01
ZBH's EV-to-EBITDA is ranked higher than
51% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 18.40 vs. ZBH: 18.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZBH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 11.3 Max: 34
Current: 18.01
5.6
34
EV-to-Revenue 4.30
ZBH's EV-to-Revenue is ranked lower than
59% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 3.64 vs. ZBH: 4.30 )
Ranked among companies with meaningful EV-to-Revenue only.
ZBH' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 3.6 Max: 6.4
Current: 4.3
1.9
6.4
PEG Ratio 8.80
ZBH's PEG Ratio is ranked lower than
83% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ZBH: 8.80 )
Ranked among companies with meaningful PEG Ratio only.
ZBH' s PEG Ratio Range Over the Past 10 Years
Min: 0.48  Med: 2.71 Max: 146.96
Current: 8.8
0.48
146.96
Shiller PE Ratio 29.01
ZBH's Shiller PE Ratio is ranked higher than
78% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 47.20 vs. ZBH: 29.01 )
Ranked among companies with meaningful Shiller PE Ratio only.
ZBH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.09  Med: 25.6 Max: 37.32
Current: 29.01
15.09
37.32
Current Ratio 1.52
ZBH's Current Ratio is ranked lower than
78% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 2.71 vs. ZBH: 1.52 )
Ranked among companies with meaningful Current Ratio only.
ZBH' s Current Ratio Range Over the Past 10 Years
Min: 1.36  Med: 2.78 Max: 4.28
Current: 1.52
1.36
4.28
Quick Ratio 0.83
ZBH's Quick Ratio is ranked lower than
85% of the 329 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ZBH: 0.83 )
Ranked among companies with meaningful Quick Ratio only.
ZBH' s Quick Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.7 Max: 3.13
Current: 0.83
0.83
3.13
Days Inventory 346.58
ZBH's Days Inventory is ranked lower than
87% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 141.33 vs. ZBH: 346.58 )
Ranked among companies with meaningful Days Inventory only.
ZBH' s Days Inventory Range Over the Past 10 Years
Min: 298.21  Med: 327.94 Max: 349.41
Current: 346.58
298.21
349.41
Days Sales Outstanding 69.72
ZBH's Days Sales Outstanding is ranked lower than
53% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 66.85 vs. ZBH: 69.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZBH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.9  Med: 70.48 Max: 88.03
Current: 69.72
64.9
88.03
Days Payable 55.98
ZBH's Days Payable is ranked lower than
52% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 61.22 vs. ZBH: 55.98 )
Ranked among companies with meaningful Days Payable only.
ZBH' s Days Payable Range Over the Past 10 Years
Min: 42.16  Med: 49.59 Max: 68.22
Current: 55.98
42.16
68.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.81
ZBH's Dividend Yield % is ranked lower than
64% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 1.24 vs. ZBH: 0.81 )
Ranked among companies with meaningful Dividend Yield % only.
ZBH' s Dividend Yield % Range Over the Past 10 Years
Min: 0.28  Med: 0.82 Max: 1.1
Current: 0.81
0.28
1.1
Dividend Payout Ratio 0.30
ZBH's Dividend Payout Ratio is ranked higher than
74% of the 128 Companies
in the Global Medical Devices industry.

( Industry Median: 0.39 vs. ZBH: 0.30 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ZBH' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.11  Med: 0.19 Max: 1.14
Current: 0.3
0.11
1.14
3-Year Dividend Growth Rate 2.90
ZBH's 3-Year Dividend Growth Rate is ranked lower than
65% of the 77 Companies
in the Global Medical Devices industry.

( Industry Median: 10.20 vs. ZBH: 2.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ZBH' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.9
Current: 2.9
0
6.9
Forward Dividend Yield % 0.81
ZBH's Forward Dividend Yield % is ranked lower than
75% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 1.53 vs. ZBH: 0.81 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.07
ZBH's 5-Year Yield-on-Cost % is ranked lower than
61% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 1.54 vs. ZBH: 1.07 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ZBH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.37  Med: 1.09 Max: 1.46
Current: 1.07
0.37
1.46
3-Year Average Share Buyback Ratio -6.10
ZBH's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 247 Companies
in the Global Medical Devices industry.

( Industry Median: -5.70 vs. ZBH: -6.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZBH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.3  Med: 1.6 Max: 7.5
Current: -6.1
-8.3
7.5

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.31
ZBH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 122 Companies
in the Global Medical Devices industry.

( Industry Median: 2.37 vs. ZBH: 1.31 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ZBH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.14 Max: 2.24
Current: 1.31
0.65
2.24
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.23
ZBH's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
90% of the 29 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ZBH: 1.23 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ZBH' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.65  Med: 1.25 Max: 12.62
Current: 1.23
0.65
12.62
Price-to-Median-PS-Value 0.99
ZBH's Price-to-Median-PS-Value is ranked higher than
53% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ZBH: 0.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ZBH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.11 Max: 2.55
Current: 0.99
0.72
2.55
Earnings Yield (Greenblatt) % 2.40
ZBH's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ZBH: 2.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZBH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 6.8 Max: 14.7
Current: 2.4
1.2
14.7
Forward Rate of Return (Yacktman) % 6.66
ZBH's Forward Rate of Return (Yacktman) % is ranked lower than
52% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 6.87 vs. ZBH: 6.66 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ZBH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.7  Med: 11.9 Max: 32.7
Current: 6.66
0.7
32.7

More Statistics

Revenue (TTM) (Mil) $7,824.10
EPS (TTM) $ 9.01
Beta1.14
Short Percentage of Float1.49%
52-Week Range $108.03 - 133.49
Shares Outstanding (Mil)202.47

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 7,927 8,145 8,428
EBIT (Mil $) 1,942 2,044
EBITDA (Mil $) 2,800 3,102 3,232
EPS ($) 8.02 8.55 9.57
EPS without NRI ($) 8.02 8.55 9.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.90%
Dividends per Share ($) 1.06 1.20

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}